Drugmakers should devise a COVID-19 vaccine that targets omicron and its sub-variants alongside the original strain, advisers to the Food and Drug Administration said Tuesday after a robust debate about how to keep up with the swiftly evolving virus.
FDA official: New-look COVID-19 booster campaign could start in October →